Aminosyn Ii
Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartic Acid, Glutamic Acid, Histidine, Proline, Serine, N-acetyltyrosine, And Glycine
Hospira, Inc.
Human Prescription Drug
NDC 0409-7171Aminosyn Ii also known as Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartic Acid, Glutamic Acid, Histidine, Proline, Serine, N-acetyltyrosine, And Glycine is a human prescription drug labeled by 'Hospira, Inc.'. National Drug Code (NDC) number for Aminosyn Ii is 0409-7171. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Aminosyn Ii drug includes Alanine - 1490 mg/100mL Arginine - 1527 mg/100mL Aspartic Acid - 1050 mg/100mL Glutamic Acid - 1107 mg/100mL Glycine - 750 mg/100mL Histidine - 450 mg/100mL Isoleucine - 990 mg/100mL Leucine - 1500 mg/100mL Lysine Acetate - 1575 mg/100mL Methionine - 258 mg/100mL and more. The currest status of Aminosyn Ii drug is Active.
Drug Information:
| Drug NDC: | 0409-7171 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Aminosyn Ii |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Isoleucine, Leucine, Lysine Acetate, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartic Acid, Glutamic Acid, Histidine, Proline, Serine, N-acetyltyrosine, And Glycine |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Hospira, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Injection, Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | ALANINE - 1490 mg/100mL ARGININE - 1527 mg/100mL ASPARTIC ACID - 1050 mg/100mL GLUTAMIC ACID - 1107 mg/100mL GLYCINE - 750 mg/100mL HISTIDINE - 450 mg/100mL ISOLEUCINE - 990 mg/100mL LEUCINE - 1500 mg/100mL LYSINE ACETATE - 1575 mg/100mL METHIONINE - 258 mg/100mL
Load more...N-ACETYLTYROSINE - 405 mg/100mL PHENYLALANINE - 447 mg/100mL PROLINE - 1083 mg/100mL SERINE - 795 mg/100mL THREONINE - 600 mg/100mL TRYPTOPHAN - 300 mg/100mL VALINE - 750 mg/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | INTRAVENOUS
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 19 Dec, 1991 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 01 Dec, 2023 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | NDA020041 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 16 Jan, 2026 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Hospira, Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 800188 800192 800237 800241
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| NUI: | N0000175780 M0000922
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | OF5P57N2ZX 94ZLA3W45F 30KYC7MIAI 3KX376GY7L TE7660XO1C 4QD397987E 04Y7590D77 GMW67QNF9C TTL6G7LIWZ AE28F7PNPL
Load more...DA8G610ZO5 47E5O17Y3R 9DLQ4CIU6V 452VLY9402 2ZD004190S 8DUH1N11BX HG18B9YRS7
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class EPC: | Amino Acid [EPC]
|
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. |
| Pharmacologic Class CS: | Amino Acids [CS]
|
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. |
| Pharmacologic Class: | Amino Acid [EPC] Amino Acids [CS]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 0409-7171-17 | 6 POUCH in 1 CASE (0409-7171-17) / 1 BAG in 1 POUCH / 2000 mL in 1 BAG | 19 Dec, 1991 | 01 Dec, 2023 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Aminosyn ii isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, glutamic acid, histidine, proline, serine, n-acetyltyrosine, and glycine isoleucine isoleucine leucine leucine lysine acetate lysine methionine methionine phenylalanine phenylalanine threonine threonine tryptophan tryptophan valine valine alanine alanine arginine arginine aspartic acid aspartic acid glutamic acid glutamic acid histidine histidine proline proline serine serine n-acetyltyrosine n-acetyltyrosine glycine glycine sodium hydroxide aminosyn ii isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, glutamic acid, histidine, proline, serine, n-acetyltyrosine, and glycine isoleucine isoleucine leucine leucine lysine acetate lysine methionine methionine phenylalanine phenylalanine threonine threonine tryptophan tryptophan valine valine alanine alanine arginine arginine aspartic acid aspartic acid glutamic acid glutamic acid histidine histidine proline proline serine serine n-acetyltyrosine n-acetyltyrosine glycine glycine sodium hydroxide
Drug Interactions:
Drug interactions because of its antianabolic activity, concurrent administration of tetracycline may reduce the potential effects of amino acids infused with dextrose as part of a parenteral feeding regimen.
Boxed Warning:
Pharmacy bulk package â not for direct infusion.
Indications and Usage:
Indications and usage aminosyn ii, sulfite-free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. supplemental electrolytes, in accordance with the prescription of the attending physician, must be added to aminosyn ii solutions without electrolytes. aminosyn ii can be administered peripherally with dilute (5 to 10%) dextrose solution and i.v. fat emulsion as a source of nutritional support. this form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. aminosyn ii is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used and gastr
Read more...ointestinal absorption of protein is impaired.
Warnings:
Warnings intravenous infusion of amino acids may induce a rise in blood urea nitrogen (bun), especially in patients with impaired hepatic or renal function. appropriate laboratory tests should be performed periodically and infusion discontinued if bun levels exceed normal postprandial limits and continue to rise. it should be noted that a modest rise in bun normally occurs as a result of increased protein intake. administration of amino acid solutions to a patient with hepatic insufficiency may result in serum amino acid imbalances, metabolic alkalosis, prerenal azotemia, hyperammonemia, stupor and coma. administration of amino acid solutions in the presence of impaired renal function may augment an increasing bun, as does any protein dietary component. solutions containing sodium ion should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. solutions which c
Read more...ontain potassium ion should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. solutions containing acetate ion should be used with great care in patients with metabolic or respiratory alkalosis. acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. hyperammonemia is of special significance in infants, as it can result in mental retardation. therefore, it is essential that blood ammonia levels be measured frequently in infants. instances of asymptomatic hyperammonemia have been reported in patients without overt liver dysfunction. the mechanisms of this reaction are not clearly defined, but may involve genetic defects and immature or subclinically impaired liver function. warning: this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. tissue loading may occur even at lower rates of administration.
Dosage and Administration:
Dosage and administration each 100 ml of aminosyn ii contains: amino acids nitrogen aminosyn ii 10% 10 g 1.53 g aminosyn ii 15% 15 g 2.30 g the total daily dose of the solution depends on the daily protein requirements and on the patientâs metabolic and clinical response. in many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. to prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose infusions are abruptly discontinued. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. color variation from pale yellow to yellow is normal and does not alter efficacy. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solutio
Read more...n quality or safety. the opacity will diminish gradually. aminosyn ii in the 2000 ml flexible pharmacy bulk package is designed for use with manual, gravity flow operations and automated gravimetric compounding devices for preparing intravenous nutritional admixtures. admixtures must be stored under refrigeration and used within 24 hours of admixing. peripheral vein nutritional maintenance a mixture of aminosyn ii and dextrose diluted to a final concentration of 5% to 10% amino acids and 5% to 10% dextrose is suitable for administration by peripheral vein. this solution is not intended for central vein administration because it does not contain adequate amounts of amino acids or electrolytes. for peripheral intravenous infusion, 1 to 1.5 g/kg/day of total amino acids will reduce protein catabolism. infusion or ingestion of carbohydrate or lipid will not reduce the nitrogen sparing effect of intravenous amino acid infusions at this dose. as with all intravenous fluid therapy, the primary aim is to provide sufficient water to compensate for insensible, urinary and other (nasogastric suction, fistula drainage, diarrhea) fluid losses. total fluid requirements, as well as electrolyte and acid-base needs, should be estimated and appropriately administered. for an amino acid solution of specified total concentration, the volume required to meet amino acid requirements per 24 hours can be calculated. after making an estimate of the total daily fluid (water) requirement, the balance of fluid needed beyond the volume of amino acid solution required can be provided either as a noncarbohydrate or a carbohydrate-containing electrolyte solution. i.v. lipid emulsion may be substituted for part of the carbohydrate-containing solution. vitamins and additional electrolytes as needed for maintenance or to correct imbalances may be added to the amino acid solution. if desired, only one-half of an estimated daily amino acid requirement of 1.5 g/kg can be given on the first day. amino acids together with dextrose in concentrations of 5% to 10% infused into a peripheral vein can be continued while oral nutrition is impaired. however, if a patient is unable to take oral nourishment for a prolonged period of time, institution of total parenteral nutrition with exogenous calories should be considered. central vein total parenteral nutrition for central vein infusion with concentrated dextrose solution, alone or with i.v. lipid, the total daily dose of the amino acid solution depends upon daily protein requirements and the patientâs metabolic and clinical response. the determination of nitrogen balance and accurate daily body weights, corrected for fluid balance, are probably the best means of assessing individual protein requirements. adults solutions containing 3.5 to 5% amino acids with 5 to 10% glucose may be infused with a fat emulsion by peripheral vein to provide approximately 1400 to 2000 kcal/day. fat emulsion administration should be considered when prolonged parenteral nutrition is required in order to prevent essential fatty acid deficiency (e.f.a.d.). serum lipids should be monitored for evidence of e.f.a.d. in patients maintained on fat-free tpn. aminosyn ii solution should only be infused via a central vein when admixed with sufficient dextrose to provide full caloric requirements in patients who require prolonged total parenteral nutrition. i.v. lipid may be administered to provide part of the calories, if desired. serum lipids should be monitored for evidence of essential fatty acid deficiency in patients maintained on fat-free tpn. total parenteral nutrition (tpn) may be started with 10% dextrose added to the calculated daily requirement of amino acids (1.5 g/kg for a metabolically stable patient). dextrose content is gradually increased over the next few days to the estimated daily caloric need as the patient adapts to the increasing amounts of dextrose. each gram of dextrose provides approximately 3.4 kcal. each gram of fat provides 9 kcal. the average depleted major surgical patient with complications requires between 2500 and 4000 kcal and between 12 and 24 grams of nitrogen per day. an adult patient in an acceptable weight range with restricted activity who is not hypermetabolic, requires about 30 kcal/kg of body weight/day. average daily adult fluid requirements are between 2500 and 3000 ml and may be much higher with losses from fistula drainage or severe burns. typically, a hospitalized patient may lose 12 to 18 grams of nitrogen a day, and in severe trauma the daily loss may be 20 to 25 grams or more. aminosyn ii solutions without electrolytes are intended for patients requiring individualized electrolyte therapy. sodium, chloride, potassium, phosphate, calcium and magnesium are major electrolytes which should be added to aminosyn ii as required. serum electrolytes should be monitored as indicated. electrolytes may be added to the nutrient solution as indicated by the patientâs clinical condition and laboratory determinations of plasma values. major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. vitamins, including folic acid and vitamin k, are required additives. the trace element supplements should be given when long-term parenteral nutrition is undertaken. iron is added to the solution or given intramuscularly in depot form as indicated. vitamin b 12 , vitamin k and folic acid are given intramuscularly or added to the solution as desired. calcium and phosphorus additives are potentially incompatible when added to the tpn admixture. in patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. in adults, hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the vena cava. typically, each liter of central vein tpn solution for adults contains 42.5 to 50 g of aminosyn ii with approximately 250 ± 100 g of dextrose; supplementary nonprotein calories from intravenous fat emulsion may be prescribed, at the discretion of the physician. the rate of intravenous infusion initially should be 2 ml/min and may be increased gradually. if administration should fall behind schedule, no attempt to âcatch upâ to planned intake should be made. in addition to meeting protein needs, the rate of administration is governed by the patientâs glucose tolerance estimated by glucose levels in blood and urine. aminosyn ii solution, when mixed with an appropriate volume of concentrated dextrose, offers a higher concentration of calories and nitrogen per unit volume. this solution is indicated for patients requiring larger amounts of nitrogen than could otherwise be provided or where total fluid load must be kept to a minimum, for example, patients with renal failure. provision of adequate calories in the form of hypertonic dextrose may require exogenous insulin to prevent hyperglycemia and glycosuria. to prevent rebound hypoglycemia, do not abruptly discontinue administration of nutritional solutions. pediatric pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram. amino acids are probably best administered in a 2.5% concentration. for most pediatric patients on intravenous nutrition, 2.5 grams amino acids/kg/day with dextrose alone or with i.v. lipid calories of 100 to 130 kcal/kg/day is recommended. in cases of malnutrition or stress, these requirements may be increased. it is acceptable in pediatrics to start with a nutritional solution of half strength at a rate of about 60 to 70 ml/kg/day. within 24 to 48 hours the volume and concentration of the solution can be increased until the full strength pediatric solution (amino acids and dextrose) is given at a rate of 125 to 150 ml/kg/day. supplemental electrolytes and vitamin additives should be administered as deemed necessary by careful monitoring of blood chemistries and nutritional status. addition of iron is more critical in the infant than the adult because of the increasing red cell mass required for the growing infant. serum lipids should be monitored for evidence of essential fatty acid deficiency in patients maintained on fat-free tpn. bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. to ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in infants, accurately calibrated and reliable infusion systems should be used. a basic solution for pediatric use should contain 25 grams of amino acids and 200 to 250 grams of glucose per 1000 ml, administered from containers containing 250 or 500 ml. such a solution given at the rate of 145 ml/kg/day provides 130 kcal/kg/day. recommended directions for use of the pharmacy bulk package use aseptic technique during use, container must be stored, and all manipulations performed, in an appropriate laminar flow hood. remove cover from outlet port at bottom of container. insert piercing pin of sterile transfer set and suspend unit in a laminar flow hood. insertion of a piercing pin into the outlet port should be performed only once in a pharmacy bulk package solution. once the outlet site has been entered, the withdrawal of container contents should be completed promptly in one continuous operation. should this not be possible, a maximum time of 4 hours from transfer set pin or implement insertion is permitted to complete fluid transfer operations; i.e., discard container no later than 4 hours after initial closure puncture. sequentially dispense aliquots of aminosyn ii into i.v. containers using appropriate transfer set. during fluid transfer operations, the pharmacy bulk package should be maintained under the storage conditions recommended in the labeling. additives may be incompatible with fluid withdrawn from this container. consult with pharmacist, if available. when compounding admixtures, use aseptic technique. mix thoroughly. do not store solutions containing additives. because of the potential for life-threatening events, caution should be taken to ensure that precipitates have not formed in any parenteral nutrient mixture. warning: do not use flexible container in series connections.
Contraindications:
Contraindications this preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.
Adverse Reactions:
Adverse reactions peripheral infusions a 3.5% to 5% solution of amino acids (without additives) is slightly hypertonic. use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. electrolyte additives should be spread throughout the day. irritating additive medications may need to be infused at another venous site. generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions.
Drug Interactions:
Drug interactions because of its antianabolic activity, concurrent administration of tetracycline may reduce the potential effects of amino acids infused with dextrose as part of a parenteral feeding regimen.
Use in Pregnancy:
Pregnancy category c. animal reproduction studies have not been conducted with aminosyn ii (an amino acid injection). it is not known whether aminosyn ii can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. aminosyn ii should be given to a pregnant woman only if clearly needed.
Pediatric Use:
Pediatric use: safety and effectiveness of solutions from flexible plastic containers in pediatric patients have not been well established. clinical evaluation and laboratory determinations, at the discretion of the attending physician, are necessary for proper monitoring during administration. do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen containing substances may occur. blood studies should include glucose, urea nitrogen, serum electrolytes, ammonia, cholesterol, acid-base balance, serum proteins, kidney and liver function tests, osmolarity and hemogram. white blood count and blood cultures are to be determined if indicated. urinary osmolality and glucose should be determined as necessary.
Geriatric Use:
Geriatric use: clinical studies of aminosyn ii have not been performed to determine whether patients over 65 years of age respond differently from younger subjects. other reported clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by kidney, and the risk for adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Overdosage:
Overdosage in the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (see warnings and precautions .)
Description:
Description aminosyn ⢠ii, sulfite-free, (an amino acid injection) is a sterile, nonpyrogenic solution for intravenous infusion. aminosyn ii is oxygen sensitive. the pharmacy bulk package is a sterile dosage form which contains multiple single doses for use only in a pharmacy bulk admixture program. the formulations are described below: essential amino acids (mg/100 ml) aminosyn ii 10% 15% isoleucine 660 990 leucine 1000 1500 lysine (acetate)* 1050 1575 methionine 172 258 phenylalanine 298 447 threonine 400 600 tryptophan 200 300 valine 500 750 *amount cited is for lysine alone and does not include the acetate. nonessential amino acids (mg/100 ml) alanine 993 1490 arginine 1018 1527 l-aspartic acid 700 1050 l-glutamic acid 738 1107 histidine 300 450 proline 722 1083 serine 530 795 n-acetyl-l-tyrosine 270 405 glycine 500 750 other characteristics protein equivalent (approx. grams/liter) 100 150 total nitrogen (grams/liter) 15.3 23.0 osmolarity (mosmol/liter, actual) 840 1270 ph a 5.8 (5.0 â 6.5) 5.8 (5.0 â 6.5) specific gravity 1.03 1.05 electrolytes (meq/l) sodium (na + ) b 38 50 acetate (c 2 h 3 o 2 - ) c 71.8 107.6 a solution contains sodium hydroxide for ph adjustment. b figure includes na + from the ph adjustor. c includes acetate from lysine acetate. the flexible plastic container is fabricated from a specially formulated polyvinylchloride. water can permeate from inside the container into the overwrap but not in amounts to affect the solution significantly. solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. exposure to temperatures above 25°c/77°f during transport and storage will lead to minor losses in moisture content. higher temperatures lead to greater losses. it is unlikely that these minor losses will lead to clinically significant changes within the expiration period. the formulas for the individual amino acids are as follows: the pharmacy bulk package is designed for use with manual, gravity flow operations and automated compounding devices for preparing sterile parenteral nutrient admixtures; it contains no bacteriostat. multiple single doses may be dispensed during continual aliquoting operations. withdrawal of container contents should be promptly completed within 4 hours after initial closure puncture. structural formula amino acids
Clinical Pharmacology:
Clinical pharmacology aminosyn ii, sulfite-free, (an amino acid injection) provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. aminosyn ii, given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (tpn). aminosyn ii can also be administered by peripheral vein with dextrose and maintenance electrolytes. intravenous fat emulsion may be substituted for part of the carbohydrate calories during either tpn or peripheral vein administration of aminosyn ii.
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility: studies with solutions from flexible plastic containers have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
How Supplied:
How supplied aminosyn ii is supplied as a pharmacy bulk package in a 2000 ml flexible container for continuous admixture compounding procedures. two concentrations are available: aminosyn ii 10%, sulfite-free ndc 0409-7172-17 aminosyn ii 15%, sulfite-free ndc 0409-7171-17 store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. avoid exposure to light. revised: november, 2010 printed in usa en-2701 hospira, inc., lake forest, il 60045 usa
Package Label Principal Display Panel:
Im-2038 iv bag ndc 0409-7171-17
Im-2118 iv bag ndc 0409-7172-17